Change of Serum Antithyroglobulin Antibody Levels Is Useful for Prediction of Clinical Recurrence in Thyroglobulin-Negative Patients with Differentiated Thyroid Carcinoma
Open Access
- 1 December 2008
- journal article
- other
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 93 (12) , 4683-4689
Abstract
Objectives: The aim of the study was to evaluate the usefulness of the antithyroglobulin autoantibody (TgAb) value at 6–12 months after remnant ablation in predicting recurrence in differentiated thyroid carcinoma patients who had undetectable thyroglobulin (Tg) values. The change in TgAb concentration measured between the time of remnant ablation (TgAb1) and 6–12 months thereafter (TgAb2) was also evaluated as a possible prognostic indicator. Patients and Methods: Patients with differentiated thyroid carcinoma who underwent total thyroidectomy followed by 131I remnant ablation between 1995 and 2003 at the Asan Medical Center (Seoul, Korea) were enrolled. Of these, 824 patients with undetectable Tg at 6–12 months after remnant ablation during thyroid hormone withdrawal were the subjects of this study. Results: TgAb2 was positive in 56 patients. Ten of 56 patients (18%) with positive TgAb2 had recurrence, whereas only 10 of 768 patients (1%) with negative TgAb2 had recurrence during 73.6 months of follow-up (P < 0.001). The change between TgAb1 and TgAb2 levels was evaluated in patients with positive TgAb2. TgAb concentration decreased by more than 50% in 21 patients (group 1) and by less than 50% in 16 patients (group 2), and it increased in 19 patients (group 3). The recurrence rates in groups 1, 2, and 3 were 0, 19, and 37%, respectively (P = 0.016). Conclusions: Serum TgAb levels measured at 6–12 months after remnant ablation could predict recurrence in patients with undetectable Tg values. In patients with undetectable Tg and positive TgAb values, a change in TgAb concentration during the early postoperative period may be a prognostic indicator of recurrence.Keywords
This publication has 20 references indexed in Scilit:
- European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epitheliumEuropean Journal of Endocrinology, 2006
- Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines TaskforceThyroid®, 2006
- Serum Thyroglobulin Levels at the Time of131I Remnant Ablation Just after Thyroidectomy Are Useful for Early Prediction of Clinical Recurrence in Low-Risk Patients with Differentiated Thyroid CarcinomaThe Journal of Clinical Endocrinology & Metabolism, 2005
- Prognostic Value of Thyroglobulin Serum Levels and 131 I Whole-Body Scan after Initial Treatment of Low-Risk Differentiated Thyroid CancerThyroid®, 2004
- Laboratory Support for the Diagnosis and Monitoring of Thyroid DiseaseThyroid®, 2003
- Diagnostic 131-Iodine Whole-Body Scan May Be Avoided in Thyroid Cancer Patients Who Have Undetectable Stimulated Serum Tg Levels After Initial TreatmentThe Journal of Clinical Endocrinology & Metabolism, 2002
- Is Diagnostic Iodine-131 Scanning Useful after Total Thyroid Ablation for Differentiated Thyroid Cancer?The Journal of Clinical Endocrinology & Metabolism, 2000
- Influence of Lymphocytic Thyroiditis on the Prognostic Outcome of Patients with Papillary Thyroid CarcinomaThe Journal of Clinical Endocrinology & Metabolism, 1999
- Significance of Antithyroglobulin Autoantibodies in Differentiated Thyroid CarcinomaThyroid®, 1994
- A high prevalence of thyroglobulin autoantibodies in adults with and without thyroid disease as measured with a sensitive solid-phase immunosorbent radioassayClinical Immunology and Immunopathology, 1985